Esperion Therapeutics, Inc. (ESPR) Stock

Esperion Therapeutics, Inc. (ESPR) is a Healthcare stock trading at $3.15 (as of 2026-06-18), with a market capitalization of $805.76M and a trailing P/E of -113490714045710336.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Valuation — source: SEC EDGAR (first-party)
Price$3.15
Market Cap$805.76M
P/E Ratio-113490714045710336.0
EV / EBITDA8.6
Price / Book-2.63
Price / Sales1.94
DCF Value (model)$-0.21
DCF Upside vs Price-106.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$403.13M
Net Margin-5.6%
Return on Equity2.4%
Current Ratio1.53
Revenue Growth (YoY)21.3%
EPS Growth (YoY)-60.7%
FCF Growth (YoY)-45.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.54 (distress)
Valuation vs Sector & Industry
Stock P/E-113490714045710336.0
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-541481451888840384.0%
vs Industry-657493672847170944.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($55.30M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSheldon L. Koenig
Employees304
CountryUS
IPO Date2013-06-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • GH Research PLC (GHRS)
  • Rigel Pharmaceuticals, Inc. (RIGL)
  • Spyre Therapeutics, Inc. (SYRE)
  • MapLight Therapeutics, Inc. (MPLT)
  • Anavex Life Sciences Corp. (AVXL)
  • Jade Biosciences, Inc. (JBIO)
  • Arvinas, Inc. (ARVN)
  • Fulcrum Therapeutics, Inc. (FULC)
ESPR earnings history · ESPR institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.